The DOI matches its Crossref record.
Renal Safety and Tolerability of Celecoxib, a Novel Cyclooxygenase-2 Inhibitor
Abstract
The novel cyclooxygenase- (COX)-2 inhibitor celecoxib is an effective treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis. Conventional treatment for these debilitating conditions routinely involves the use of conventional nonsteroidal anti-inflammatory drugs (NSAIDs), which are nonspecific inhibitors of COX-1 and COX-2. Numerous studies suggest that inhibition of renal prostaglandin synthesis by NSAIDs is deleterious to kidney function, particularly in high-risk patients. As celecoxib inhibits COX-2 and spares COX-1 at therapeutic doses, we hypothesized that it may offer an improved renal safety profile in patients at risk for NSAID-induced renal toxicity. This article represents a post hoc analysis of the renal safety of celecoxib, using the safety database generated during its clinical development program. This analysis includes data from more than 50 clinical studies involving more than 13,000 subjects. Most subjects were enrolled in randomized, controlled trials (of up to 12 weeks' duration); however, more than 5000 subjects received celecoxib for as long as 2 years in a long-term, open-label study at as much as twice the maximum recommended dosage. The overall incidence of renal adverse events after celecoxib was greater than that after placebo but similar to that after NSAIDs. The most common events reported after celecoxib, namely, peripheral edema (2.1%), hypertension (0.8%), and exacerbation of preexisting hypertension (0.6%), were not time- or dose-related. Peripheral edema was not associated with increased weight or blood pressure. Furthermore, there was no evidence of drug-drug interactions between celecoxib and concomitant angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, calcium channel blockers, or diuretics. We conclude that celecoxib is well tolerated by patients who may be at risk for NSAID-induced renal toxicity, such as the elderly and those with hypertension or preexisting chronic heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
The Management of Persistent Pain in Older Persons: AGS Panel on Persistent Pain in Older Persons
(2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.50.6s.1.x · Cited by 1,139
Harirforoosh, S., Asghar, W., & Jamali, F. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vw2f · Cited by 960
Therapeutic Strategies for Rheumatoid Arthritis
O'Dell, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040226 · Cited by 588
Cyclooxygenase-2—10 Years Later
Hinz, B., & Brune, K. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.367 · Cited by 518
Metadata
- Authors
- Whelton, A., Maurath, C. J., Verburg, K. M., & Geis, G. S.
- Venue
- American Journal of Therapeutics
- Published
- 2000-05
- Volume
- 7
- Issue
- 3
- Pages
- 159-174
- ISSN
- 1075-2765 (ISSN-L)
- OpenAlex
- W1978759500
- Cited by
- 167
- References
- 0
- FWCI
- 15.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal Safety and Tolerability of Celecoxib, a Novel Cyclooxygenase-2 Inhibitor. https://app.cochat.ai/papers/10.1097/00045391-200007030-00004
- The paper
- Whelton, A., Maurath, C. J., Verburg, K. M., & Geis, G. S. (2000). Renal Safety and Tolerability of Celecoxib, a Novel Cyclooxygenase-2 Inhibitor. American Journal of Therapeutics. https://doi.org/10.1097/00045391-200007030-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.